TABLE 1.
Baseline Clinical and Demographic Characteristics of Participants Receiving Either Placebo or Active Treatments During Acute Treatment, Followed by Open Active Treatment
| Characteristic | Total (N=439) | Placebo/Open Treatment (N=112)a | Active Treatments (N=327)b | |||
|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | Mean | SD | |
| Age (years) | 14.6 | 1.5 | 14.5 | 1.6 | 14.6 | 1.5 |
| Children’s Depression Rating Scale–Revised score | 60.1 | 10.4 | 61.1 | 10.5 | 59.8 | 10.3 |
| Clinical Global Impression, severity score | 4.8 | 0.8 | 4.8 | 0.8 | 4.7 | 0.8 |
| Children’s Global Assessment Scale score | 49.6 | 7.5 | 49.1 | 7.6 | 49.8 | 7.4 |
| Duration of current episode (weeks) | 71.6 | 82.4 | 61.2 | 67.4 | 75.2 | 86.7 |
| Number of current comorbid disorders | 0.9 | 1.1 | 0.9 | 1.1 | 0.9 | 1.1 |
| N | % | N | % | N | % | |
| Female | 239 | 54.4 | 59 | 52.7 | 180 | 55.1 |
| First major depressive episode | 369 | 86.0 | 93 | 84.6 | 276 | 86.5 |
| Current comorbid disorders | ||||||
| Dysthymia | 46 | 10.5 | 12 | 10.7 | 34 | 10.4 |
| Attention deficit hyperactivity disorder | 60 | 13.7 | 19 | 17.0 | 41 | 17.0 |
| Anxiety disorders | 120 | 27.4 | 28 | 25.2 | 92 | 28.1 |
| Disruptive behavior disorders | 103 | 23.5 | 75 | 22.9 | 28 | 25.0 |
a
Twelve weeks of placebo treatment followed by open active treatment as clinically indicated.
b
Treatment with fluoxetine, cognitive-behavioral therapy (CBT), or combination treatment with fluoxetine and CBT.